AI Article Synopsis
- Screening for hepatocellular carcinoma (HCC) is crucial for high-risk individuals, such as those with cirrhosis or chronic hepatitis B or C infections.
- A study involving over 18,000 high-risk patients showed that biannual screening decreased HCC-related deaths by 37%.
- The recommended screening method is ultrasound imaging, which should be conducted every 6 months.
Article Abstract
Screening for hepatocellular carcinoma (HCC) should be implemented in the high-risk population. High-risk population includes patients with cirrhosis of any etiology, patients with chronic hepatitis B virus with or without cirrhosis, and patients with chronic hepatitis C virus with cirrhosis. A randomized controlled trial of over 18,000 high-risk individuals demonstrated that biannual screening reduced HCC-related mortality by 37%. The screening test of choice is ultrasound imaging with an interval of 6 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinimag.2015.11.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatitis B and C virus infection among couples undergoing premarital screening in Iraqi Kurdistan.
IJID Reg
March 2025
College of Medicine, Department of Clinical Science, University of Zakho, Zakho, Iraq.
Background And Objectives: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are significant global health challenges, leading to severe complications such as liver cirrhosis and hepatocellular carcinoma. Despite available vaccines and treatments, these infections persist, particularly, in regions such as Iraq. This study aimed to assess the prevalence of HBV and HCV among couples attending premarital screening programs in Zakho, Kurdistan Region of Iraq and explore the associated demographic risk factors.
View Article and Find Full Text PDFTrace element zinc metabolism and its relation to tumors.
Front Endocrinol (Lausanne)
December 2024
Department of Urology, Kunming Children's Hospital, Kunming, Yunnan, China.
Zinc is an essential trace element in the human body, playing a crucial role in cellular metabolism.Dysregulation of zinc homeostasis can lead to abnormal cellular metabolism, contributing to diseases and closely related to tumor development. Adequate zinc intake can maintain zinc homeostasis in the body and support normal cellular metabolism.
View Article and Find Full Text PDFRole of arbutin in the inhibition of FBXO5 in hepatocellular carcinoma.
Discov Oncol
December 2024
Department of Hygiene, School of Public Health, Bengbu Medical University, Bengbu, 233030, Anhui, People's Republic of China.
Purpose: This work investigated the effect of FBXO5 in hepatocellular carcinoma (HCC) and the mechanism of action of arbutin in its inhibition.
Methods: FBXO5 mRNA and protein expressions in the tumor were assessed using TCGA, ICGC and HPA databases. Cox regression analysis and Kaplan-Meier survival curves were employed to assess the impact of FBXO5 on the survival outcomes of patients with HCC.
Harnessing the Power of AI for Enhanced Diagnosis and Treatment of Hepatocellular Carcinoma.
Turk J Gastroenterol
December 2024
Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China.
Since its advent, artificial intelligence (AI) has been continuously researched, and substantial progress has been made in many fields, such as the diagnosis and therapies for cancer. Due to the advantages of high efficiency, rapidity, and precision, AI has been increasingly adopted in the medical field to improve patient prognosis and the efficiency of medical procedures. Thus, AI technology has become a powerful driving force and support mechanism in the medical and health industry.
View Article and Find Full Text PDFCarnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease liver cancer stem cell activation.
World J Gastroenterol
December 2024
Department of Immunology, Medical School, Nantong University, Nantong 226001, Jiangsu Province, China.
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the main chronic liver diseases. However, the roles of mitochondrial carnitine palmitoyl transferase-II (CPT-II) downregulation and liver cancer stem cell (LCSC) activation remain to be identified.
Aim: To investigate the dynamic alterations in CPT-II inactivity and LCSC activation during the malignant progression of MAFLD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!